"In men with prostate cancer, regular aspirin use is associated with a slower rate of disease progression and a reduced risk of dying from the disease, according to a new study.
The findings come from an analysis of data from the large"...
Viadur® (leuprolide acetate implant) , like other LH-RH agonists, causes a transient increase in serum concentrations of testosterone during the first week of treatment. Patients may experience worsening of symptoms or onset of new symptoms, including bone pain, neuropathy, hematuria, or ureteral or bladder outlet obstruction (see PRECAUTIONS).
If spinal cord compression or renal impairment develops, standard treatment of these complications should be instituted.
Patients with metastatic vertebral lesions and/or with urinary tract obstruction should be closely observed during the first few weeks of therapy (see WARNINGS).
X-rays do not affect Viadur® (leuprolide acetate implant) functionality. Viadur® (leuprolide acetate implant) is radio-opaque and is well visualized on X-rays.
The titanium alloy reservoir of Viadur® (leuprolide acetate implant) is nonferromagnetic and is not affected by magnetic resonance imaging (MRI). Slight image distortion around Viadur® (leuprolide acetate implant) may occur during MRI procedures.
Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Hyperglycemia may represent development of diabetes mellitus or worsening of glycemic control in patients with diabetes. Monitor blood glucose and/or glycosylated hemoglobin (HbA1c) periodically in patients receiving a GnRH agonist and manage with current practice for treatment of hyperglycemia or diabetes.
Increased risk of developing myocardial infarction, sudden cardiac death and stroke has been reported in association with use of GnRH agonists in men. The risk appears low based on the reported odds ratios, and should be evaluated carefully along with cardiovascular risk factors when determining a treatment for patients with prostate cancer. Patients receiving a GnRH agonist should be monitored for symptoms and signs suggestive of development of cardiovascular disease and be managed according to current clinical practice.
Information for Patients
An information leaflet for patients is included with the product.
Response to Viadur® (leuprolide acetate implant) should be monitored by measuring serum concentrations of testosterone and prostate-specific antigen periodically.
Results of testosterone determinations are dependent on assay methodology. It is advisable to be aware of the type and precision of the assay methodology to make appropriate clinical and therapeutic decisions.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Two-year carcinogenicity studies were conducted in rats and mice. In rats, dose-related increases of benign pituitary hyperplasia and benign pituitary adenomas were noted at 24 months when the drug was administered subcutaneously at high daily doses (4 to 24 mg/m², 50 to 300 times the daily human exposure based on body surface area). There were significant but not dose-related increases of pancreatic islet-cell adenomas in females and of testicular interstitial cell adenomas in males (highest incidence in the low dose group). In mice no pituitary abnormalities were observed at up to 180 mg/m² (over 2000 times the daily human exposure based on body surface area) for 2 years.
Mutagenicity studies were performed with leuprolide acetate using bacterial and mammalian systems. These studies provided no evidence of a mutagenic potential.
Pregnancy Category X (see CONTRAINDICATIONS).
Viadur® (leuprolide acetate implant) is contraindicated in pediatric patients and was not studied in children
(see CONTRAINDICATIONS).This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 3/20/2017
Additional Viadur Information
Viadur - User Reviews
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.